Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

published today in Lancet Haematology suggest that patients with a type of blood cancer called Chronic Lymphocytic Leukaemia (CLL) who are being treated with Bruton Tyrosine Kinase inhibitors ...

Fusions can also cause deactivation of the protein’s tyrosine ... gene fusions in cancer. Ann Oncol. 2019;30(suppl 8):viii5-viii15. 9. Federman N, McDermott R. Larotrectinib, a highly selective ...

The review discusses the early trials of multikinase tyrosine kinase inhibitors (TKIs) that were initially used to treat RET-altered thyroid cancer and NSCLC, with limited success. The development ...

These are grouped according to the way they work. For thyroid cancer, doctors use a type of targeted drug called tyrosine kinase inhibitors (TKIs). TKI’s block a cancer cell chemical messenger called ...

The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting hosted by the American Association for Cancer ... small-molecule inhibitor that targets MET tyrosine kinase activity ...

The Food and Drug Administration (FDA) accepted a New Drug Application for the tyrosine kinase inhibitor, repotrectinib, for the treatment of ROS1-positive, locally advanced or metastatic non-small ...

Tyrosine kinase inhibitors are oral pills and a type of targeted therapy for thyroid cancer. Doctors prescribe these drugs more commonly than traditional chemotherapy due to their effectiveness.

Shot of an elderly man reading the contents on a bottle of medication at home Since FDA approval of imtainib, 40 newer tyrosine kinase inhibitor ... of Texas MD Anderson Cancer Center in Houston.